QIAGEN's QuantiFERON-TB Test Wins Tender for Testing of Republic of Korea Armed Forces Recruits

Friday, January 27, 2017 General News J E 4
Selected for screening of 340,000 recruits in 2017 as part of national TB control strategy

HILDEN, Germany and SEOUL, January 26, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Gold (QFT), the modern standard for accuracy in diagnosing latent tuberculosis (TB) infection, has been selected by the Republic of Korea Armed Forces for the screening of more than 340,000 recruits during 2017.

Korea has one of the highest active TB incidence rates among industrialized countries, with more than 32,000 new cases and 2,300 deaths per year. The government has adopted a strategy to eliminate the disease, including preventive screening of at-risk groups and treatment of individuals with latent tuberculosis infection (LTBI), in line with recommendations of the World Health Organization (WHO).

Furthermore, the Korea Centers for Disease Control and Prevention (CDC) in 2016 selected QuantiFERON-TB for nationwide contact screening of people at risk of infection through close contact with active TB patients.

"We are pleased to support the efforts in Korea to take a comprehensive, best-practice approach to TB control, and are collaborating with authorities, distributors and laboratories to implement a program for latent TB screening using QuantiFERON-TB as the modern test of choice," said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN. QuantiFERON-TB is the standard test used by national laboratories in Korea and won this competitive tender for the Republic of Korea Armed Forces based on its proven workflow and cost effectiveness."

Click here for the full press release{AB5927E4-128B-4D19-BCDE-E0DA1E5395CE}&lang=en

Contacts: QIAGEN Investor Relations John Gilardi +49-2103-29-11711 e-mail: Public Relations Dr. Thomas Theuringer     +49-2103-29-11826 e-mail:




You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s announces strategic agreem...
Breakthrough Therapies: Market Dynamics and Invest...